All In Biotech

Drug Trial Radar · NCT00925301

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations

Last checked: Nov 19, 2026Latest source record: Oct 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

67

Actual

Start

Oct 23, 2009

Primary completion

Jun 12, 2012

Study completion Jan 29, 2014

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to compare the effect of migalastat (123 milligrams \[mg\] of migalastat \[equivalent to 150 mg of migalastat hydrochloride\]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).

Conditions

  • Fabry Disease

Interventions

  • migalastat hydrochlorideDrug

    Oral capsule QOD

  • PlaceboDrug

    Oral capsule QOD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) InclusionsTime frame: Baseline, Month 6

Locations

28 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Decatur, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Boston, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    New York, New York

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Springfield, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Adelaide, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Cairo, Egypt

  • Site not named

    Garches, France

  • Site not named

    Roma, Italy

  • Site not named

    Warsaw, Poland

  • Site not named

    Barcelona, Spain

  • Site not named

    Zaragoza, Spain

  • Site not named

    Ankara, Turkey (Türkiye)

  • Site not named

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.